TG4050 and TG4070 advance as individualized neoantigen vaccines, with TG4070 entering phase I for lung cancer and leveraging the in-house SNIPER platform. Manufacturing shifts to scalable cell lines, supporting faster, automated production and expansion into new indications, including Monkeypox and Smallpox vaccines.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.